Non-annotated gene. Preliminary data : if you are an author who wish to write a full paper/card on this gene, contribute in submission tool
Other Information
Locus ID:
NCBI: 64757
MIM: 614126
HGNC: 26189
Ensembl: ENSG00000186205
Variants:
dbSNP: 64757
ClinVar: 64757
TCGA: ENSG00000186205
COSMIC: MTARC1
RNA/Proteins
| Gene ID | Transcript ID | Uniprot |
|---|---|---|
| ENSG00000186205 | ENST00000366910 | Q5VT66 |
| ENSG00000186205 | ENST00000407981 | H7BYZ9 |
| ENSG00000186205 | ENST00000443880 | X6RIL1 |
| ENSG00000186205 | ENST00000463976 | H0YDX4 |
Pathways
| Pathway | Source | External ID |
|---|---|---|
| Metabolism | REACTOME | R-HSA-1430728 |
| Biological oxidations | REACTOME | R-HSA-211859 |
| Phase 1 - Functionalization of compounds | REACTOME | R-HSA-211945 |
References
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 38340654 | 2024 | Fatty liver disease protective MTARC1 p.A165T variant reduces the protein stability of MTARC1. | 1 |
| 38375985 | 2024 | Mitochondrial amidoxime-reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome. | 2 |
| 38437227 | 2024 | Divergent role of Mitochondrial Amidoxime Reducing Component 1 (MARC1) in human and mouse. | 1 |
| 38619429 | 2024 | mARC1 in MASLD: Modulation of lipid accumulation in human hepatocytes and adipocytes. | 0 |
| 38723751 | 2024 | Biochemical and functional characterization of the p.A165T missense variant of mitochondrial amidoxime-reducing component 1. | 0 |
| 38340654 | 2024 | Fatty liver disease protective MTARC1 p.A165T variant reduces the protein stability of MTARC1. | 1 |
| 38375985 | 2024 | Mitochondrial amidoxime-reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome. | 2 |
| 38437227 | 2024 | Divergent role of Mitochondrial Amidoxime Reducing Component 1 (MARC1) in human and mouse. | 1 |
| 38619429 | 2024 | mARC1 in MASLD: Modulation of lipid accumulation in human hepatocytes and adipocytes. | 0 |
| 38723751 | 2024 | Biochemical and functional characterization of the p.A165T missense variant of mitochondrial amidoxime-reducing component 1. | 0 |
| 35411667 | 2022 | Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms. | 15 |
| 36233117 | 2022 | Association of MARC1, ADCY5, and BCO1 Variants with the Lipid Profile, Suggests an Additive Effect for Hypertriglyceridemia in Mexican Adult Men. | 2 |
| 36555467 | 2022 | MTARC1 and HSD17B13 Variants Have Protective Effects on Non-Alcoholic Fatty Liver Disease in Patients Undergoing Bariatric Surgery. | 5 |
| 35411667 | 2022 | Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms. | 15 |
| 36233117 | 2022 | Association of MARC1, ADCY5, and BCO1 Variants with the Lipid Profile, Suggests an Additive Effect for Hypertriglyceridemia in Mexican Adult Men. | 2 |
Citation
Dessen P
MTARC1 (mitochondrial amidoxime reducing component 1)
Atlas Genet Cytogenet Oncol Haematol. 2014-11-01
Online version: http://atlasgeneticsoncology.org/gene/68804/mtarc1-(mitochondrial-amidoxime-reducing-component-1)
